| Symbol | RNAZ |
|---|---|
| Name | TRANSCODE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 6 LIBERTY SQUARE,SUITE 2382, BOSTON, Massachusetts, 02109, United States |
| Telephone | +1 857 837-3099 |
| Fax | — |
| — | |
| Website | https://www.transcodetherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001829635 |
| Description | TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The companys lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. Additional info from NASDAQ: |
(99% Neutral) TRANSCODE THERAPEUTICS, INC. (RNAZ) Announces Business Combination
Read more(85% Positive) TRANSCODE THERAPEUTICS, INC. (RNAZ) Announces Clinical Development Update
Read moreNew Form ARS - Transcode Therapeutics, Inc. <b>Filed:</b> 2026-06-02 <b>AccNo:</b> 0001104659-26-069488 <b>Size:</b> 3 MB
Read moreNew Form DEF 14A - Transcode Therapeutics, Inc. <b>Filed:</b> 2026-06-02 <b>AccNo:</b> 0001104659-26-069458 <b>Size:</b> 3 MB
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreTransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
Read moreNew Form DEFA14A - Transcode Therapeutics, Inc. <b>Filed:</b> 2026-05-26 <b>AccNo:</b> 0001104659-26-065966 <b>Size:</b> 28 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06260774 | Study of TTX-MC138 in Subjects With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Active_Not_Recruiting | 2024-09-05 | 2027-02-01 | ClinicalTrials.gov |
| NCT05908773 | A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumo… | Early_Phase1 | Advanced Solid Tumor | Completed | 2023-04-04 | 2023-09-18 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| TTX-MC138-NODAGA-Cu64 | Other | Phase EARLY_PHASE1 | Advanced Solid Tumor | COMPLETED | NCT05908773 |
| TTX-MC138 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06260774 |